Latham & Watkins represented NewLimit in the financing. NewLimit has announced that it has raised $40 million in a Series A funding round from Dimension, Founders Fund,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented CG Oncology in the transaction. CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Medallion in the financing. Medallion, the modern provider management platform, has announced US$35 million in Series C funding, raising its total funding...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Mineralys Therapeutics in the transaction. Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Xepelin on the deal. Latham & Watkins and Barros & Errázuriz and Ritch, Mueller y Nicolau represented Avenir. Carey advised Manutara Ventures and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Clarify Health in the transaction. Clarify Health, a leading cloud analytics and value-based payments platform company, has announced that it secured US$150...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Zerigo Health in the financing. Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Convex in the transaction. Convex, the software platform leading the commercial services industry’s digital-first revolution, has raised US$39 million in its Series B...
You must be a Standard 1 Year member to access this content.
